Concord Biotech Limited vs Natco Pharma Limited
Last updated: 23 October 2026
Concord Biotech Limited and Natco Pharma Limited are two prominent Indian pharmaceutical companies that often come under the scanner for investors looking for opportunities in the healthcare sector. While Concord Biotech specializes in fermentation-based biopharmaceutical products, Natco Pharma focuses on niche therapeutic areas, including oncology and hepatitis C. Both companies operate in a dynamic and highly regulated industry, making their financial performance, market valuation, and growth prospects crucial for potential investors. This comparison aims to provide a clear, data-driven analysis of their current market standing based on key metrics, helping MoneyDock readers make informed decisions.
Key Financial Metrics Comparison
| Metric | Concord Biotech Limited (CONCORDBIO.NS) | Natco Pharma Limited (NATCOPHARM.NS) |
|---|---|---|
| Current Price | ₹1270.70 | ₹785.15 |
| 52-Week High | ₹1579.40 | ₹1206.00 |
| 52-Week Low | ₹1014.80 | ₹782.65 |
| 1-Year Return | -7.88% | -14.79% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
When we look at the current market prices, Concord Biotech is trading at ₹1270.70, significantly higher than Natco Pharma's ₹785.15. However, price alone doesn't indicate valuation. With the Trailing P/E and Market Cap listed as N/A for both companies, a comprehensive valuation comparison is challenging based on the provided data. Investors would typically look at these metrics to assess if a stock is over or undervalued relative to its earnings and market size.
In terms of returns, both companies have experienced negative performance over the past year. Concord Biotech shows a 1-Year Return of -7.88%, which, while negative, is better than Natco Pharma's -14.79%. This suggests that Concord Biotech has been more resilient or has faced fewer headwinds compared to Natco Pharma over the last twelve months. For investors focused purely on recent performance, Concord Biotech has offered a less steep decline.
Regarding stability and volatility, we can look at the 52-week high and low ranges. Concord Biotech has a 52-week range of ₹1014.80 to ₹1579.40, indicating a range of ₹564.60. Natco Pharma, on the other hand, has a range from ₹782.65 to ₹1206.00, a difference of ₹423.35. While Concord Biotech's absolute price movement is larger, Natco Pharma's current price of ₹785.15 is very close to its 52-week low of ₹782.65, suggesting it is trading near its annual floor, which could indicate either potential stability at this level or a lack of upward momentum. Concord Biotech's current price of ₹1270.70 is closer to its 52-week low than its high, but not as critically positioned as Natco Pharma.
MoneyDock Verdict
MoneyDock Verdict
For Aggressive Investors: Given that Natco Pharma is currently trading very close to its 52-week low and has a steeper 1-year negative return, aggressive investors might see this as a potential 'buy on dip' opportunity, assuming they have a strong conviction in its future recovery and growth prospects. Concord Biotech's relatively better 1-year return might offer less dramatic upside for an aggressive play based on current figures alone.
For Conservative Investors: Both companies have negative 1-year returns, making them less appealing for strictly conservative investors seeking capital preservation and steady gains in the immediate term. However, if forced to choose, Concord Biotech, with its less severe negative 1-year return (-7.88% vs -14.79%), presents a slightly less volatile recent performance and might be perceived as marginally safer, albeit still risky given the overall negative trend.
For Long-Term SIP Investors: For long-term SIP investors, the absence of Trailing P/E and Market Cap data makes it difficult to assess intrinsic value and long-term growth potential definitively. However, both companies operate in a robust pharmaceutical sector. SIP investors might consider regularly investing in either, focusing on the long-term industry growth rather than short-term price fluctuations. Concord Biotech's slightly better relative performance over the last year could suggest better underlying resilience, but this needs to be coupled with deeper fundamental analysis beyond the provided numbers for a solid long-term SIP decision.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.